|
gptkbp:instanceOf
|
gptkb:drug
triptan
|
|
gptkbp:approvedBy
|
1997
|
|
gptkbp:ATCCode
|
N02CC02
|
|
gptkbp:bioavailability
|
74%
|
|
gptkbp:brand
|
Amerge
Naramig
|
|
gptkbp:CASNumber
|
143388-64-1
|
|
gptkbp:chemicalFormula
|
C17H25N3O2
|
|
gptkbp:contraindication
|
ischemic heart disease
uncontrolled hypertension
cerebrovascular syndrome
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
naratriptan
|
|
gptkbp:KEGGID
|
D08213
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
serotonin 5-HT1B/1D receptor agonist
|
|
gptkbp:MedlinePlusID
|
a698051
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
311.4 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
29%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1391
54713
60723
DB00952
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
drowsiness
dry mouth
|
|
gptkbp:synonym
|
Naratriptan hydrochloride
|
|
gptkbp:UNII
|
YAA2D9TX5N
|
|
gptkbp:usedFor
|
migraine
|
|
gptkbp:bfsParent
|
gptkb:triptans
|
|
gptkbp:bfsLayer
|
7
|